Illumina Announces Plan to Release One-Million-SNP Genotyping BeadChips by June 2006.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Customer Consortium to Leverage Flexibility of Infinium(TM) Assay to Optimize SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily Content and Scientific Value Illumina, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ILMN) announced today that it plans to release by June 2006 a whole-genome microarray offering that will utilize the Company's new Infinium(TM) assay and enable researchers to genotype genotype (jēn`ətīp'): see genetics. genotype Genetic makeup of an organism. The genotype determines the hereditary potentials and limitations of an individual. one million SNPs on a pair of Sentrix(R) BeadChips. Single BeadChip offerings containing 250,000 and 500,000 fixed-content SNP markers will be developed and released on the path to the million-SNP product. Development of the high-density genotyping product line will take advantage of three important factors: --Illumina's proprietary Infinium assay, a PCR-less, fully automatable, single-tube genotyping assay that is infinitely scaleable and enables unconstrained locus selection for maximal genome coverage, data quality and information content --Near-term availability of validated HapMap, cSNP and nsSNP content and increased understanding of the relative scientific value of SNP markers, allowing design of information-rich products --Manufacturing infrastructure that Illumina has put in place for the upcoming launch of its Sentrix Human-1 exon-centric genotyping BeadChip. Now in beta testing (programming) beta testing - Testing a pre-release (potentially unreliable) version of a piece of software by making it available to selected users. This term derives from early 1960s terminology for product cycle checkpoints, first used at IBM but later standard throughout the , the Human-1 BeadChip contains over 100,000 SNPs, nearly 30,000 of which are located in genes; another 40,000 of which are within 10KB of genes. Illumina will work closely with a customer consortium to help ensure that SNP content delivers the industry's highest per-marker value for disease association, linkage disequilibrium linkage disequilibrium n. The nonrandom association between two or more alleles such that certain combinations of alleles are more likely to occur together on a chromosome than other combinations of alleles. and related studies requiring dense, genome-wide coverage. Illumina (www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray(TM) technology -- now used in leading genome centers around the world -- provides the throughput, cost effectiveness and flexibility to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine  The external links in this article or section may require cleanup to comply with Wikipedia's content policies. . "Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " Statement under the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. with Affymetrix, the Company's ability to scale and integrate CyVera technology, the ability to further scale oligo synthesis output and technology to satisfy market demand deriving from the Company's collaboration with Invitrogen, Illumina's ability to further develop and commercialize its Infinium assay and BeadArray platform technologies, to deploy new gene expression and genotyping products and applications for its platform technology, to manufacture robust Sentrix(R) arrays and Oligator(R) oligonucleotides, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion